( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release

Seiichiro Shimazu, Kazue Takahata, Hiroshi Katsuki, Hiroko Tsunekawa, Akie Tanigawa, Fumio Yoneda, J. Knoll, Akinori Akaike

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

"Catecholaminergic and serotoninergic activity enhancer" effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [( - )-BPAP HCl], a compound with selective and potent "catecholaminergic and serotoninergic activity enhancer" effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. ( - )-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3-10 mg/kg). ( - )-BPAP HCl (1-3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of ( - )-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R( + )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of ( - )-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of ( - )-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by ( - )-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, ( - )-BPAP HCl significantly improved ptosis. These findings suggested that a "catecholaminergic and serotoninergic activity enhancer" compound, ( - )-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalEuropean Journal of Pharmacology
Volume421
Issue number3
DOIs
Publication statusPublished - Jun 15 2001

Fingerprint

Locomotion
Dopamine
Reserpine
Antiparkinson Agents
Amantadine
Dopamine D1 Receptors
Dopamine Antagonists
Apomorphine
Oxidopamine
Catecholamines
Parkinson Disease
1-(benzofuran-2-yl)-2-propylaminopentane
Serotonin
Animal Models
Observation
Brain

Keywords

  • ( - )-Deprenyl
  • 6-Hydroxydopamine
  • [( - )-BPAP HCl] ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride
  • Catecholaminergic and serotoninergic activity enhancer
  • Parkinson's disease
  • Reserpine

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. / Shimazu, Seiichiro; Takahata, Kazue; Katsuki, Hiroshi; Tsunekawa, Hiroko; Tanigawa, Akie; Yoneda, Fumio; Knoll, J.; Akaike, Akinori.

In: European Journal of Pharmacology, Vol. 421, No. 3, 15.06.2001, p. 181-189.

Research output: Contribution to journalArticle

Shimazu, Seiichiro ; Takahata, Kazue ; Katsuki, Hiroshi ; Tsunekawa, Hiroko ; Tanigawa, Akie ; Yoneda, Fumio ; Knoll, J. ; Akaike, Akinori. / ( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. In: European Journal of Pharmacology. 2001 ; Vol. 421, No. 3. pp. 181-189.
@article{c009da8ec8834c12963ff480bf2714e3,
title = "( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release",
abstract = "{"}Catecholaminergic and serotoninergic activity enhancer{"} effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [( - )-BPAP HCl], a compound with selective and potent {"}catecholaminergic and serotoninergic activity enhancer{"} effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. ( - )-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3-10 mg/kg). ( - )-BPAP HCl (1-3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of ( - )-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R( + )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of ( - )-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of ( - )-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by ( - )-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, ( - )-BPAP HCl significantly improved ptosis. These findings suggested that a {"}catecholaminergic and serotoninergic activity enhancer{"} compound, ( - )-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.",
keywords = "( - )-Deprenyl, 6-Hydroxydopamine, [( - )-BPAP HCl] ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride, Catecholaminergic and serotoninergic activity enhancer, Parkinson's disease, Reserpine",
author = "Seiichiro Shimazu and Kazue Takahata and Hiroshi Katsuki and Hiroko Tsunekawa and Akie Tanigawa and Fumio Yoneda and J. Knoll and Akinori Akaike",
year = "2001",
month = "6",
day = "15",
doi = "10.1016/S0014-2999(01)01040-8",
language = "English",
volume = "421",
pages = "181--189",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - ( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release

AU - Shimazu, Seiichiro

AU - Takahata, Kazue

AU - Katsuki, Hiroshi

AU - Tsunekawa, Hiroko

AU - Tanigawa, Akie

AU - Yoneda, Fumio

AU - Knoll, J.

AU - Akaike, Akinori

PY - 2001/6/15

Y1 - 2001/6/15

N2 - "Catecholaminergic and serotoninergic activity enhancer" effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [( - )-BPAP HCl], a compound with selective and potent "catecholaminergic and serotoninergic activity enhancer" effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. ( - )-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3-10 mg/kg). ( - )-BPAP HCl (1-3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of ( - )-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R( + )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of ( - )-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of ( - )-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by ( - )-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, ( - )-BPAP HCl significantly improved ptosis. These findings suggested that a "catecholaminergic and serotoninergic activity enhancer" compound, ( - )-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.

AB - "Catecholaminergic and serotoninergic activity enhancer" effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [( - )-BPAP HCl], a compound with selective and potent "catecholaminergic and serotoninergic activity enhancer" effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. ( - )-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3-10 mg/kg). ( - )-BPAP HCl (1-3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of ( - )-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R( + )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of ( - )-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of ( - )-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by ( - )-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, ( - )-BPAP HCl significantly improved ptosis. These findings suggested that a "catecholaminergic and serotoninergic activity enhancer" compound, ( - )-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.

KW - ( - )-Deprenyl

KW - 6-Hydroxydopamine

KW - [( - )-BPAP HCl] ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride

KW - Catecholaminergic and serotoninergic activity enhancer

KW - Parkinson's disease

KW - Reserpine

UR - http://www.scopus.com/inward/record.url?scp=0035876074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035876074&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(01)01040-8

DO - 10.1016/S0014-2999(01)01040-8

M3 - Article

VL - 421

SP - 181

EP - 189

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -